# Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment

> **NCT03706625** · — · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 201 (actual)

## Conditions studied

- Non Hodgkin Lymphoma
- Non Small Cell Lung Cancer
- Glioma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03706625
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-20
- **Primary completion:** 2023-07-06
- **Final completion:** 2023-07-06
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03706625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03706625, "Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03706625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*